National Resilience sells Massachusetts manufacturing plant for $125M but plans to lease it back

National Resilience, a biopharma manufacturing specialist, inked a third sale-leaseback real estate deal with Oxford Properties for a nearly completed 120,000-square-foot production facility in Marlborough, Massachusetts.

As part of the deal, Oxford acquired the site for $125 million and will lease the property back to Resilience for up to 30 years.

The transaction expands Oxford’s portfolio in North America to 1.4 million square feet, the company said in a press release last week. Oxford has an additional development pipeline of more than 1 million square feet.

“We continue to develop a robust expertise on the real estate needs of biomanufacturing and our footprint in this space is a key pillar of our investment strategy to build a global life sciences business of scale," Chad Remis, Oxford’s executive vice president, North America, said in the release.

When opened, the Marlborough facility will offer best-in-class specifications and multimodality manufacturing capabilities, including dedicated manufacturing suites, office and warehouse space.

Oxford Properties is a global real estate developer operating in eight business sectors. Its North American pharma manufacturing outfit comprises 12 facilities in six regions. The company owns around 775,000 square feet of pharma manufacturing space in the Boston area.

Oxford didn't disclose the location of the other two Resilience sale-leaseback deals.

For its part, Resilience has raised more than $1 billion since August 2021. Since its founding in 2020, the company has been busy expanding its manufacturing network and partnering with pharma companies—and others—to strengthen global drug supply chains.

Last August, the company inked a manufacturing partnership with the Mayo Clinic to produce biologics derived from sources like cells, blood, enzymes, tissues, genes or genetically engineered cells. The deal with Mayo came fast on the heels of a partnership with the University of Texas MD Anderson Cancer Center.

Last week, Resilience revealed it had signed a 10-year deal with a "leading pharmaceutical company" to provide a range of manufacturing services.